Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells

Anti-Cancer Drugs

Volumn 10, Issue 7, 1999, Pages 655-661

  Lawrence, Richard A ^a   Izbicka, Elzbieta ^a   De Jager, Robert L ^b   Tohgo, Akiko ^c   Clark, Gary M ^d   Weitman, Steven D ^a   Rowlnsky, Eric K ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b Daiichi Pharmaceutical Corporation   (United States)

^c DAIICHI SANKYO CO   (Japan)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Camptothecin; DX 8951f; Human tumor cloning; Topoisomerase I inhibitors; Topotecan

Indexed keywords

ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; EXATECAN; UNCLASSIFIED DRUG;

ARTICLE; COLONY FORMATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0032841228     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199908000-00005     Document Type: Article

References (25)

1. 1. Liu L. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989, 58: 315-75.
2. 2. Barry M, Reynolds J, Eastman A. Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 1993; 53: 2349-57.
3. 3. Evans D, Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hempatoma cells and nonproliferating immature thymocytes. Cancer Res 1993; 53: 2133-9.
4. 4. Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochem Biophys Acta 1993; 1175: 147-54.
5. 5. Smith P, Soues S, Gottlieb T, Falk S, et al. Etoposideinduced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br J Cancer 1994; 70: 914-21.
6. 6. Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995; 86: 776-82.
7. 7. Mitsui I, Kumezawa E, Hirota Y. Antitumor activity of DX-8951f, a new camptothecin derivative. Proc Am Ass Cancer Res 1993; 34: 421.
8. 8. Hamburger AW, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest 1977; 60: 846-57.
9. 9. Hamburger AW, Salmon SE, Primary bioassay of human tumor stem cells. Science 1977; 197: 461.
10. 10. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Eng J Med 1978; 298: 1321-7.
11. 11. Von Hoff DD, Casper J, Bradley E, Jones D, Makuch R, Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 1981; 70: 1027-32.
12. 12. Von Hoff DD, Clark GM, Stogdill BJ, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983; 43: 1926-31.
13. 13. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 1990; 82: 110-6.
14. 14. Shoemaker RH, Wolpert-Defillipes MK, Kern DH, et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Rex 1985; 45: 2145-53.
15. 15. Von Hoff DD, Coltman CA, Jr, Forseth B. Activity of Mitoxantrone in a human tumor cloning system. Cancer Res 1981; 41: 1853-5.
16. 16. Rowinsky E, Verweij J. Review of phase I clinical studies with topotecan. Semin Oncol 1997; 24: S20-3-10.
17. 17. Wall M, Wani M, Cooke C, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3388-90.
18. 18. Gottlieb J, Guarino A, Call J, VT O, Block J. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 1970; 54: 461-70.
19. 19. Moertel C, Schutt A, Reitemeier R. Phase II study of campththecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95-101.
20. 20. Muggia F, Creven P, Hansen H, Cohen M, Selawry O. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): correlation with preclinical studies. Cancer Chemother Rep 1972, 56: 515-21.
21. 21. Rothenberg M. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837-55.
22. 22. Kumazawa E, Jimbo T, Oichi Y, Tohgo A. Potent and broad antitumor effects of DX-8951f, a water soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother Phamacol 1999; in press.
23. 23. Joto N, Ishii M, Minami M, Kuga H, Mitsui I, Tohgo A. DX8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int J Cancer 1997; 72: 680-6.
24. 24. Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A. Antitumor effect of DX-8951f, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.Jpn J Cancer Res 1997; 88: 760-9.
25. 25. Johnson T, Geyer C, De Jager R, et al. Phase I and pharmacokinetic (PK) study of DX-8951f, a novel hexacyclic camptothecin (CPT) analog, on a 30 minute infusion daily for 5 day every 3 week schedule. Proc Am Soc. Clin Oncol 1998; 17: 196A.